Fulgent Genetics Partners with Foundation Medicine to Transform Hereditary Cancer Risk Assessment

### Fulgent Genetics Partners with Foundation Medicine to Enhance Cancer Risk Assessment

Fulgent Genetics, a prominent player in genomic testing, collaborates with Foundation Medicine, Inc. to launch two innovative germline tests aimed at revolutionizing hereditary cancer risk assessment. These tests, named FoundationOne® Germline and FoundationOne® Germline More, are set to debut in the U.S. on February 28, 2025. Designed to detect genetic variants linked to hereditary cancers, these tests will support healthcare providers in evaluating the cancer risks for patients and their families. By integrating these offerings with Foundation Medicine’s extensive genomic profiling tests, the collaboration promises to enhance the precision of cancer diagnostics and treatment planning.

FoundationOne Germline is a next-generation sequencing (NGS) test that analyzes 50 genes associated with hereditary cancers, specifically tailored for individuals with pertinent personal or family histories of cancer. In contrast, FoundationOne Germline More expands the analysis to 154 genes, making it suitable for patients with more complex clinical presentations. This comprehensive approach allows healthcare providers to gain critical insights into the genetic underpinnings of cancer, thereby improving the accuracy of risk assessments. Annie Murphy, chief commercial officer at Foundation Medicine, underscores that these tests will not only aid in determining cancer origins but also inform future health risks, thereby enhancing the overall value provided to both healthcare professionals and patients.

The integration of Fulgent’s proprietary technology into these tests marks a significant advancement in the field of molecular diagnostics. Brandon Perthuis, chief commercial officer at Fulgent, emphasizes the importance of combining germline and somatic testing, which leverages the strengths of both companies to push the boundaries of patient care. As Foundation Medicine continues to lead in molecular profiling, the partnership with Fulgent Genetics exemplifies a commitment to advancing clinical care and research in cancer treatment, paving the way for more personalized and effective healthcare solutions.

The collaboration between Fulgent Genetics and Foundation Medicine signifies a noteworthy development in the genomics landscape, particularly in cancer care. By providing healthcare providers with advanced tools to assess genetic risks, the companies aim to empower patients and improve clinical outcomes. This partnership not only enhances the diagnostic capabilities available to clinicians but also reflects a broader trend towards personalized medicine in oncology.

As the healthcare industry increasingly recognizes the importance of genetic testing in cancer risk assessment, Fulgent Genetics stands to play a pivotal role in this transformation. The launch of these new germline tests could set a new standard for how hereditary cancers are diagnosed and managed, ultimately contributing to better patient care and more informed treatment strategies.